MedTrace Logo

Ocular Surface Health and Tear Film Stability With a Nasal Spray Dry Eye Treatment

NCT07606625 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2026-05-27

No results posted yet for this study

Summary

The purpose of this study is to examine the impact of nasal spray treatment on Meibomian gland function and ocular surface health in symptomatic dry eye patients with mild to moderate Meibomian gland dysfunction (MGD).

Conditions

  • Dry Eye
  • Meibomian Gland Dysfunction

Interventions

DRUG

Varenicline 0.03Mg/Spray Nasal Soln

After meeting eligibility criteria and signing informed consent, participants will be dispensed a 3-month supply of varenicline 0.03mg/spray nasal solution. Participants will take the nasal spray home and spray once in each nostril twice daily for 3 months

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-06
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07606625 on ClinicalTrials.gov